Pharmaceutical firm Ranbaxy Labs has reported a consolidated net loss of Rs 465 crore in the third quarter of 2011 as against Rs 308 crore in the corresponding quarter of last fiscal. The loss was due to the forex loss of Rs 400 crore in the quarter.
Additional loss arising out of derivatives MTM stood at Rs 251 crore during the same period.
Net sales moved up 7.7% to Rs 2,022 crore in the July-September quarter of 2011 versus Rs 1,877 crore in a year ago period.
EBITDA margins improved at 8.3% versus 7.2%, which included other operating income.
Source: www.moneycontrol.com
Thanks,
Gaurav Agarwal
Head Dealer
DENIP Consultants Pvt Ltd
No comments:
Post a Comment